Physician profile
Manuel Martinez
NPI 1427151489
$3,145.67
in general payments reported to CMS, 2019-2025
42 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $155 · 2021: $731 · 2022: $909 · 2023: $503 · 2024: $56.25 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $370.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $337.68 | 2021-2025 | |
| Pfizer INC. | $220.05 | 2019-2023 | |
| Novo Nordisk INC | $210.95 | 2021-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $190.43 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $173.46 | 2021-2025 | |
| Esperion Therapeutics, INC. | $164.71 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $116.66 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $115.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $112.47 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $109.52 | 2023 | Watchman Flx |
| Amarin Pharma, INC. | $106.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $103.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.79 | 2020-2025 | Jardiance |
| Amgen INC. | $83.97 | 2019-2023 | Otezla, Repatha |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.